# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

> **NCT01206517** · PHASE1 · COMPLETED · sponsor: **Organon and Co** · enrollment: 30 (actual)

## Conditions studied

- Schizophrenia
- Bipolar I Disorder

## Interventions

- **DRUG:** Asenapine 2.5 mg
- **DRUG:** Asenapine 5 mg
- **DRUG:** Asenapine 10 mg

## Key facts

- **NCT ID:** NCT01206517
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-18
- **Primary completion:** 2011-08-04
- **Final completion:** 2011-08-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206517, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01206517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*